Imaging of gastrinomas by nuclear medicine methods

Wiener Klinische Wochenschrift

Volumn 119, Issue 19-20, 2007, Pages 593-596

  Béhé, Martin ^a,c   Gotthardt, Martin ^b   Behr, Thomas M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Gastrinoma; Localisation; Somatostatin receptor scintigraphy; Staging

Indexed keywords

DOPA; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR 2; TRACER;

ABDOMINAL SCINTISCANNING; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; GASTRINOMA; GENE OVEREXPRESSION; HUMAN; ISOTOPE LABELING; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL INSTRUMENTATION; POSITRON EMISSION TOMOGRAPHY; ZOLLINGER ELLISON SYNDROME;

DISEASE PROGRESSION; DUODENAL NEOPLASMS; GASTRINOMA; GASTRINS; HUMANS; INDIUM RADIOISOTOPES; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASM STAGING; OCTREOTIDE; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY;

EID: 35848940263     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-007-0881-5     Document Type: Article

References (23)

1. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30: 781-793
2. Reubi JC, Schar JC, Waser B, et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27: 273-282
3. Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28: 836-846
4. Krenning EP, Kwekkeboom DJ, Bakker WH, et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731
5. van Eijck CH, Lamberts SW, Lemaire LC, et al (1996) The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 224: 119-124
6. Plockinger U, Rindi G, Arnold R, et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumoursa. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80: 394-424
7. Ramage JK, Davies AH, Ardill J, et al (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54: iv1-16
8. Gibril F, Reynolds JC, Doppman JL, et al (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125: 26-34
9. Alexander HR, Fraker DL, Norton JA, et al (1998) Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228: 228-238
10. Jensen RT (2004) Gastrinomas: advances in diagnosis and management. Neuroendocrinology 80: 23-27
11. Norton JA, Fraker DL, Alexander HR, et al (1999) Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 34: 635-644
12. Kisker O, Bastian D, Bartsch D, Nies C, Rothmund M (1998) Localization, malignant potential, and surgical management of gastrinomas. World J Surg 22: 651-657
13. Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken EO, Wiedenmann B (2000) Endoscopic ultrasonography of neuroendocrine tumours. Digestion 62: 45-50
14. Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M (2005) Zollinger-Ellison syndrome. Chirurg 76: 217-226
15. Termanini B, Gibril F, Reynolds JC, et al (1997) Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112: 335-347
16. Gotthardt M, Dirkmorfeld LM, Wied MU, et al (2003) Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients. Digestion 68: 80-85
17. Gibril F, Reynolds JC, Chen CC, et al (1999) Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 40: 539-553
18. Eriksson B, Bergstrom M, Sundin A, et al (2002) The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci 970: 159-169
19. Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231: 305-332
20. Becherer A, Szabo M, Karanikas G, et al (2004) Imaging of advanced neuroendocrine tumors with (18) F-FDOPA PET. J Nucl Med 45: 1161-1167
21. Heppeler A, Froidevaux S, Macke HR, et al (1999) Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chemistry - A European Journal 5: 1974-1981
22. Hofmann M, Maecke H, Borner R, et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28: 1751-1757
23. Krenning EP, Valkema R, Kwekkeboom DJ, et al (2005) Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 46: 76S-82S